[
  {
    "ts": "2026-01-23T06:30:00+00:00",
    "headline": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
    "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
    "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
      "content": {
        "id": "ff057859-25cc-38ab-bf6d-78ba37dc9314",
        "contentType": "STORY",
        "title": "AbbVie Dodged a Patent Disaster, and Shares Gained 460%. Merck and Bristol Myers Are Next.",
        "description": "",
        "summary": "AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers Squibb face similar patent cliffs.",
        "pubDate": "2026-01-23T06:30:00Z",
        "displayTime": "2026-01-23T06:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ff057859-25cc-38ab-bf6d-78ba37dc9314/abbvie-dodged-a-patent.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6BytADf.wdgQOFbGSuj0IA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aiR.2Irm6EXEA73p_uJuJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/90655360b7a4e125d540f8474523bc7f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/abbvie-dodged-a-patent-disaster-and-shares-gained-460-merck-and-bristol-myers-are-next-5968f3cd?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T10:30:00+00:00",
    "headline": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
    "summary": "This biotech has candidates in late-stage clinical development.",
    "url": "https://www.fool.com/investing/2026/01/23/lilly-soared-in-2025-but-heres-another-buy/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "6899c60a-28ea-325c-8c0d-4fefc86e96ce",
      "content": {
        "id": "6899c60a-28ea-325c-8c0d-4fefc86e96ce",
        "contentType": "STORY",
        "title": "Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026",
        "description": "",
        "summary": "This biotech has candidates in late-stage clinical development.",
        "pubDate": "2026-01-23T10:30:00Z",
        "displayTime": "2026-01-23T10:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "Four investors look at something on a computer.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kDI44SVUCI_Nk6dMfOhyGQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RDwdWn3hwCTUKhIs16uN3Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e675b3d8cb6f5cdaf9f793d9878150eb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/lilly-soared-in-2025-but-heres-another-buy/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-soared-39-2025-103000601.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T14:05:26+00:00",
    "headline": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
    "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
    "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
      "content": {
        "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
        "contentType": "STORY",
        "title": "Novo's Wegovy pill hits 18,410 US prescriptions in encouraging debut week",
        "description": "",
        "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed 18,410 times in the U.S. in the first full week after its launch in an encouraging start to the oral weight-loss drug race,",
        "pubDate": "2026-01-23T14:05:26Z",
        "displayTime": "2026-01-23T14:05:26Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lmdn2ChsZZWxw2pZZm_unA--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GEkH7Pta2oCydPaYw_QgZA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/106eebc1d4c6106014e7e7be029085fd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:20:34+00:00",
    "headline": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
    "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
    "url": "https://www.fool.com/coverage/filings/2026/01/23/outfront-media-surges-40-in-one-year-then-gets-cut-loose-despite-usd0-30-dividend/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "3187d224-69cf-3a0e-b300-67aa2a71f091",
      "content": {
        "id": "3187d224-69cf-3a0e-b300-67aa2a71f091",
        "contentType": "STORY",
        "title": "Outfront Media Surges 40% in One Year, Then Gets Cut Loose Despite 'Exceptional Performance'",
        "description": "",
        "summary": "This out-of-home advertising REIT connects brands with urban audiences through a broad network of billboard and transit assets.",
        "pubDate": "2026-01-23T15:20:34Z",
        "displayTime": "2026-01-23T15:20:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vnbG7RKzagtuC1AtZnqLKA--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tpTWjRWaxFsNazxAotRGEw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/af7ec8d325cf2a320c12c354cd741265.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/01/23/outfront-media-surges-40-in-one-year-then-gets-cut-loose-despite-usd0-30-dividend/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/outfront-media-surges-40-one-152034785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "OUT"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UAN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T16:14:44+00:00",
    "headline": "Novo's Wegovy pill hits over 18,000 US prescriptions in strong debut week",
    "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U. in the first full week after its launch in an encouraging start ​to the oral weight-loss drug race, according to analysts who cited IQVIA data.",
    "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
      "content": {
        "id": "61005fb7-fee2-3624-b70b-b2dba818f6b9",
        "contentType": "STORY",
        "title": "Novo's Wegovy pill hits over 18,000 US prescriptions in strong debut week",
        "description": "",
        "summary": "By Sriparna Roy Jan 23 (Reuters) - Novo Nordisk's Wegovy pill was prescribed more than 18,000 times in the U. in the first full week after its launch in an encouraging start ​to the oral weight-loss drug race, according to analysts who cited IQVIA data.",
        "pubDate": "2026-01-23T16:14:44Z",
        "displayTime": "2026-01-23T16:14:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/3d083cbb9487caed54c121d950650d41",
          "originalWidth": 800,
          "originalHeight": 572,
          "caption": "FILE PHOTO: The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, December 3, 2025. REUTERS/Tom Little/File Photo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/R57b8cX7IAdfj9YTFGq7EA--~B/aD01NzI7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3d083cbb9487caed54c121d950650d41.cf.webp",
              "width": 800,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0YAUDxhsyXhX8ZSme1w7WA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/3d083cbb9487caed54c121d950650d41.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novos-wegovy-pill-tracks-18-123235063.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:50:47+00:00",
    "headline": "Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position",
    "summary": "Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.",
    "url": "https://www.fool.com/coverage/filings/2026/01/23/why-a-15-dividend-wasn-t-enough-to-keep-this-usd3-3-million-position/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "a633b6fd-4d8b-3a26-85ff-e16c10354d49",
      "content": {
        "id": "a633b6fd-4d8b-3a26-85ff-e16c10354d49",
        "contentType": "STORY",
        "title": "Why a 15% Dividend Wasn’t Enough to Keep This $3.3 Million Position",
        "description": "",
        "summary": "Trinity Capital provides venture debt and equipment financing to growth-stage tech companies seeking non-dilutive capital solutions.",
        "pubDate": "2026-01-23T15:50:47Z",
        "displayTime": "2026-01-23T15:50:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/beb751fe64b83c39e69071ee1b68bd95",
          "originalWidth": 1401,
          "originalHeight": 1251,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5nwNQ8HIILOLKukcfTvlYA--~B/aD0xMjUxO3c9MTQwMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/beb751fe64b83c39e69071ee1b68bd95.cf.webp",
              "width": 1401,
              "height": 1251,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cqH4vRkJDbGGu3b6AYYsIw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/beb751fe64b83c39e69071ee1b68bd95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/coverage/filings/2026/01/23/why-a-15-dividend-wasn-t-enough-to-keep-this-usd3-3-million-position/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-15-dividend-wasn-t-155047844.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "TRIN"
            },
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "GOOG"
            },
            {
              "symbol": "META"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "UAN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T13:36:00+00:00",
    "headline": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
    "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
    "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
      "content": {
        "id": "a902c7fb-d30a-336e-bdf1-87eb5d237bda",
        "contentType": "STORY",
        "title": "Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q4 Earnings",
        "description": "",
        "summary": "LLY's oncology drugs, led by Verzenio and new launches, are set to support upcoming Q4 results as investor focus broadens beyond GLP-1s.",
        "pubDate": "2026-01-23T13:36:00Z",
        "displayTime": "2026-01-23T13:36:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Zg3ykhh14An2bfVuUvzbag--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8KeSNQWO2yQtdmAEk3F_Nw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3c8c5ffebabb5a0d6f7bffb8eb41c523.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-eli-lillys-oncology-drugs-133600753.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T17:06:10+00:00",
    "headline": "Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues",
    "summary": "Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.",
    "url": "https://www.investors.com/stock-lists/sector-leaders/eli-lilly-stock-lly-orforglipron-weight-loss-drugs/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "1409ddae-e7d9-3243-bb86-3465354c45b1",
      "content": {
        "id": "1409ddae-e7d9-3243-bb86-3465354c45b1",
        "contentType": "STORY",
        "title": "Eli Lilly Stock Rebounds As Weight-Loss Drug Battle Continues",
        "description": "",
        "summary": "Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.",
        "pubDate": "2026-01-23T17:06:10Z",
        "displayTime": "2026-01-23T17:06:10Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1409ddae-e7d9-3243-bb86-3465354c45b1/eli-lilly-stock-rebounds-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/43c8bd9d3366a15a100cb01f3f6833c3",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/38rPMsn1SIiEwSmyf20MsQ--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/43c8bd9d3366a15a100cb01f3f6833c3.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RsdxpCLyWL.13dhJNDnA5Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/43c8bd9d3366a15a100cb01f3f6833c3.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/stock-lists/sector-leaders/eli-lilly-stock-lly-orforglipron-weight-loss-drugs/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NVDA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T15:36:40+00:00",
    "headline": "VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
    "summary": "The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option on the market’s continued growth. Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) combined represented nearly one-third of the ETF. If you believe the ... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
    "url": "https://247wallst.com/investing/2026/01/23/vaneck-pharmaceutical-fund-bets-big-on-weight-loss-drug-market-approaching-150-billion/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "cf14917b-c872-32ba-a34f-764f67bb10ef",
      "content": {
        "id": "cf14917b-c872-32ba-a34f-764f67bb10ef",
        "contentType": "STORY",
        "title": "VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
        "description": "",
        "summary": "The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option on the market’s continued growth. Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) combined represented nearly one-third of the ETF. If you believe the ... VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion",
        "pubDate": "2026-01-23T15:36:40Z",
        "displayTime": "2026-01-23T15:36:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a",
          "originalWidth": 686,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rq76f8F0oZe4klQDn0Hnfw--~B/aD01MTI7dz02ODY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a.cf.webp",
              "width": 686,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ALAZXFUT9E0wT0UGpJHY3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/a0d3a0e2f4155ed8d8da3ce27eac142a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/23/vaneck-pharmaceutical-fund-bets-big-on-weight-loss-drug-market-approaching-150-billion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vaneck-pharmaceutical-fund-bets-big-153640949.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "PPH"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T18:05:00+00:00",
    "headline": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
    "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
    "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
      "content": {
        "id": "d36fc022-2457-3be0-9329-dd797eed60e8",
        "contentType": "STORY",
        "title": "Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?",
        "description": "",
        "summary": "Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.",
        "pubDate": "2026-01-23T18:05:00Z",
        "displayTime": "2026-01-23T18:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A hand drawing a scale showing price vs. value.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oH1vMW9a8lQPyVxDdje.yQ--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pM7HlYM_F0inHleq4d2DMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/e6e25b0076ab1d65c4645d933a1ffa84.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/23/forget-eli-lilly-buy-these-unstoppable-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/forget-eli-lilly-buy-unstoppable-180500495.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-23T17:33:23+00:00",
    "headline": "NVIDIA (NVDA) Invests $150 million in Baseten",
    "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the Best Quantum Computing Stocks to Buy for 2026. On January 20, WSJ reported that the company is investing $150 million in Baseten, a startup that specializes in AI inference. Baseten has raised $300 million at a $5 billion valuation. This deal demonstrates NVIDIA Corporation (NASDAQ:NVDA)’s aggressive push into […]",
    "url": "https://finance.yahoo.com/news/nvidia-nvda-invests-150-million-173323306.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "502920b4-bb1b-39f3-a133-b2e8a1fc7477",
      "content": {
        "id": "502920b4-bb1b-39f3-a133-b2e8a1fc7477",
        "contentType": "STORY",
        "title": "NVIDIA (NVDA) Invests $150 million in Baseten",
        "description": "",
        "summary": "NVIDIA Corporation (NASDAQ:NVDA) is one of the Best Quantum Computing Stocks to Buy for 2026. On January 20, WSJ reported that the company is investing $150 million in Baseten, a startup that specializes in AI inference. Baseten has raised $300 million at a $5 billion valuation. This deal demonstrates NVIDIA Corporation (NASDAQ:NVDA)’s aggressive push into […]",
        "pubDate": "2026-01-23T17:33:23Z",
        "displayTime": "2026-01-23T17:33:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "NVIDIA (NVDA) Invests $150 million in Baseten",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.ZnJY6aT_ZwW.CJaMIVd5g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qEoy5Rzsl1ePc1El_kU3KA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/aa94e059977d3251b8b0630718e013fc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvidia-nvda-invests-150-million-173323306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvidia-nvda-invests-150-million-173323306.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "GROQ.PVT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]